Trial reportMicrobiome2017
Treatment of biofilms in bacterial vaginosis by an amphoteric tenside pessary-clinical study and microbiota analysis.
Trial report in Microbiome, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02687789 (A Prospective Parallel-design, Double-blind, Randomised, Controlled Investigation to Gain Clinical Experience and Further Knowledge About the Certified Medical Device Vaginal Suppository WO 3191 With Respect to Safety, Tolerability and Efficacy in the Post-Treatment of Bacterial Vaginosis), which is not on this map. Cited by 33 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Parallel-design, Double-blind, Randomised, Controlled Investigation to Gain Clinical Experience and Further Knowledge About the Certified Medical Device Vaginal Suppository WO 3191 With Respect to Safety, Tolerability and Efficacy in the Post-Treatment of Bacterial Vaginosis
Who cites it
33 citing papers in PubMed, 6 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Systems analysis of the HPV-microbiome-biofilm triad.Frontiers in cellular and infection microbiology · 2026Pooled it
- Associations of Atopobium, Garderella, Megasphaera, Prevotella, Sneathia, and Streptococcus with human papillomavirus infection, cervical intraepithelial neoplasia, and cancer: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Vaginal metatranscriptome meta-analysis reveals functional BV subgroups and novel colonisation strategies.Microbiome · 2024Pooled it
- Antibiofilm Agents for the Treatment and Prevention of Bacterial Vaginosis: A Systematic Narrative Review.The Journal of infectious diseases · 2024Pooled it
- Contribution ofFrontiers in cellular and infection microbiology · 2021Pooled it
- Lactic acid-containing products for bacterial vaginosis and their impact on the vaginal microbiota: A systematic review.PloS one · 2021Pooled it
- Adjunct vaginal lactic acid with single-dose metronidazole for bacterial vaginosis: a randomized controlled trial.BMC women's health · 2026Trial
- The urinary microbiota of men and women and its changes in women during bacterial vaginosis and antibiotic treatment.Microbiome · 2017Trial
- Vaginal Microbiota and Pelvic Floor Dysfunction: Mechanistic Insights and Therapeutic Implications.Medical science monitor : international medical journal of experimental and clinical research · 2026Review
- The Impact of the Vaginal Microbiome and Microbial Metabolites on HIV Transmission at the Female Reproductive Tract Epithelial Barrier.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Review
- Metagenomic analysis reveals the novel role of vaginal Lactobacillus iners in Chinese healthy pregnant women.NPJ biofilms and microbiomes · 2025Article
- Vaginal Microbiota and Local Immunity in HPV-Induced High-Grade Cervical Dysplasia: A Narrative Review.International journal of molecular sciences · 2025Review
- Vaginal microbiomes of breast cancer survivors treated with aromatase inhibitors with and without vulvovaginal symptoms.Scientific reports · 2024Article
- Bacterial Vaginosis: Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/028, June 2023).Geburtshilfe und Frauenheilkunde · 2023Article
- Microbiome alterations in women with pelvic organ prolapse and after anatomical restorative interventions.Scientific reports · 2023Article
- Fighting polymicrobial biofilms in bacterial vaginosis.Microbial biotechnology · 2023Review
- Bartholin's gland cyst caused by Sneathia amnii: a case report.BMC infectious diseases · 2023Article
- Article
- Article
- Contribution of Symptomatic, Herbal Treatment Options to Antibiotic Stewardship and Microbiotic Health.Antibiotics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBacterial vaginosis (BV) is the most common vaginal syndrome among women in their reproductive years. It is associated with an increased risk of acquiring sexually transmitted infections and complications like preterm labor. BV is characterized by a high recurrence rate for which biofilms frequently found on vaginal epithelial cells may be a reason.
resultsHere, we report a controlled randomized clinical trial that tested the safety and effectiveness of a newly developed pessary containing an amphoteric tenside (WO3191) to disrupt biofilms after metronidazole treatment of BV. Pessaries containing lactic acid were provided to the control group, and microbial community composition was determined via Illumina sequencing of the V1-V2 region of the 16S rRNA gene. The most common community state type (CST) in healthy women was characterized by Lactobacillus crispatus. In BV, diversity was high with communities dominated by either Lactobacillus iners, Prevotella bivia, Sneathia amnii, or Prevotella amnii. Women with BV and proven biofilms had an increased abundance of Sneathia sanguinegens and a decreased abundance of Gardnerella vaginalis. Following metronidazole treatment, clinical symptoms cleared, Nugent score shifted to Lactobacillus dominance, biofilms disappeared, and diversity (Shannon index) was reduced in most women. Most of the patients responding to therapy exhibited a L. iners CST. Treatment with WO 3191 reduced biofilms but did not prevent recurrence. Women with high diversity after antibiotic treatment were more likely to develop recurrence.
conclusionsStabilizing the low diversity healthy flora by promoting growth of health-associated Lactobacillus sp. such as L. crispatus may be beneficial for long-term female health.
trial registrationClinicalTrials.gov NCT02687789.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.